About DDB1- and CUL4-associated factor 4-like protein 1
DDB1- and CUL4-associated factor 4-like protein 1 (DCAF4L1) is a protein
from Homo sapiens identified by UniProt accession
Q3SXM0, 396 residues long.
MolForge cross-references it against 0 known binders and
16 disease associations.
Target properties
| Protein name | DDB1- and CUL4-associated factor 4-like protein 1 |
| UniProt accession | Q3SXM0 |
| Gene | DCAF4L1 |
| Organism | Homo sapiens |
| Length | 396 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (16)
Diseases linked to this target (Open Targets).
- unipolar depression · score 0.14
- bipolar disorder · score 0.12
- autism spectrum disorder · score 0.11
- anorexia nervosa · score 0.09
- attention deficit hyperactivity disorder · score 0.09
- obsessive-compulsive disorder · score 0.09
- Tourette syndrome · score 0.09
- schizophrenia · score 0.09
- depressive symptom measurement · score 0.07
- type 1 diabetes mellitus · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q3SXM0-F1 | alphafold | PREDICTED | 84.97 | — |
Amino-acid sequence (396 residues)
MEAERLRLLE EEAKLKKVAR MGFNASSMLR KSQLGFLNVT SYSRLANELR VSCMERKKVQ IRSLDPSSLA SDRFNFILAS TNSDQLFVVN QVEVEGSKYG IISLRTLKIP SFHVYVLRNL YVPNRKVKSL CWASLNQLDS HVLLCFEGIT DAPSCAVLLP ASRFLSVHTR VNQPGMLCSF QIPEAWSCAW SLNTRAYHCF SAGLSQQVLL TSVATGHQQS FDTSSDVLAQ QFASTAPLLF NGCRSGEIFA IDLRCRNRGK GWRATRLFHD SAVTSVQILQ EEQCLMASDM TGKIKLWDLR ATKCVRQYEG HVNESAYLPL HVHEEEGIVV AVGQDCYTRI WSLHDAHLLR TIPSPYSASE DDIPSVAFAS RLGGIRGAAP GLLMAVRQDL YCFPFS
Explore DDB1- and CUL4-associated factor 4-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets